Semaglutide bloating and nausea: trial data

Nausea, loose stools, and a persistent bloated feeling are the most frequently reported side effects in people starting semaglutide. They are real, they are dose-dependent, and the clinical trial data gives a clearer picture of how common they are, how long they last, and what drives them than the forum threads usually do^[1].

What the STEP trial data shows

The Wharton et al. pooled analysis of STEP 1, 2 and 3 (published in Diabetes, Obesity and Metabolism in 2022) is the most detailed breakdown of GI adverse events in the semaglutide obesity trials. Across 2,117 participants on semaglutide 2.4 mg weekly and 1,262 on placebo over 68 weeks, nausea affected 43.9% of those on semaglutide versus 16.1% on placebo^[2]. Diarrhoea affected 29.7% versus 15.9%; vomiting 24.5% versus 6.3%; constipation 24.2% versus 11.1%.

The framing the authors put on those numbers is worth reading carefully. Of all GI adverse events in the semaglutide group, 99.5% were non-serious and 98.1% were mild-to-moderate in severity. The events were concentrated during the dose-escalation period, not stable at maintenance dose. Only 4.3% of participants stopped treatment permanently because of GI symptoms.

The STEP-1 trial (Wilding et al., New England Journal of Medicine 2021) noted that nausea and diarrhoea were the most common adverse events, and that they were typically transient and mild-to-moderate in severity^[3]. In that trial, 4.5% of participants in the semaglutide group discontinued treatment due to GI events, versus 0.8% on placebo. That gap is meaningful, but it also means more than 95% of participants on semaglutide stayed on treatment.

Why GLP-1 agonists cause GI symptoms

The mechanism is not fully separate from the therapeutic effect. GLP-1 receptor agonists like semaglutide slow gastric emptying, which is part of how they extend satiety after eating^[4]. Food leaving the stomach more slowly means the stomach stays fuller for longer, which reduces appetite. It also means the stomach contents sit longer, which causes the nausea and bloating that patients report. Delayed gastric emptying is the most well-characterised motility effect of the GLP-1 class across the gastrointestinal tract.

Below the stomach, the drugs alter motility throughout the gut. Changes in transit time in the small and large intestine explain the diarrhoea some patients experience early in treatment and the constipation that can follow during the maintenance phase. Some patients get one, some get the other, and the pattern tends to shift over time as the gut adapts.

The bloating question specifically

Bloating is not a primary endpoint in the major semaglutide trials, which means trial-derived prevalence rates for bloating specifically are harder to find than for nausea or diarrhoea. Community reports on forums like r/Semaglutide put bloating high in the list of complaints, particularly in the first weeks of use. The mechanistic basis is consistent with delayed gastric emptying and altered gut motility: gas that moves through the gut more slowly is more likely to cause distension. Whether someone reports bloating versus nausea often depends on where in the GI tract the delayed transit is most pronounced.

The clinical trial data do not suggest bloating is a reason to stop. The relevant signal is whether GI symptoms are severe, progressive, or accompanied by signs that suggest something other than a class effect (such as severe abdominal pain or persistent vomiting unrelated to meals), in which case a clinician should be consulted.

What the data says about timing

The Wharton et al. analysis found that GI events are concentrated during dose escalation. Semaglutide for weight management is started at a low dose and titrated upward over several months, partly to limit GI burden. The nausea peak typically occurs around the first few weeks after each dose increase and subsides as the body adapts. Most patients who stay on the drug report the GI side effects becoming less prominent over time, which aligns with the trial data showing that maintenance-phase tolerability is better than escalation-phase tolerability.

The weight loss in STEP 1-3 was remarkably similar in participants who experienced GI events and those who did not. The Wharton analysis specifically tested whether nausea, vomiting, diarrhoea, and constipation were driving the weight loss through reduced calorie intake, and found that less than one additional percentage point of weight loss was attributable to GI adverse events. In other words, the drug's weight effect is not mainly coming from nausea forcing people to eat less. It comes from the central appetite-suppressing action. See the semaglutide overview for more on the trial evidence and the mechanism.

What we do not know yet

Long-term GI motility data beyond the 68-week trial windows is sparse. Whether the delayed gastric emptying seen during the escalation phase persists at full maintenance dose, and whether it has any clinical consequence for medication absorption (including the drug itself, in the case of oral formulations), is still being characterised in the literature. The 2025 review of GLP-1 agonist effects on gastrointestinal motility by Bellavance et al. also flagged perioperative aspiration risk in patients on GLP-1 agonists as a clinical concern requiring more study.

For the regulatory picture on semaglutide by country, the semaglutide regulation pages carry jurisdiction-specific status. The medical disclaimer below applies to everything on this page.